Vestal Point Capital LP Takes $13.76 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Vestal Point Capital LP bought a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 990,000 shares of the company's stock, valued at approximately $13,761,000. Vestal Point Capital LP owned about 1.96% of Tyra Biosciences at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Rhumbline Advisers increased its holdings in Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after buying an additional 1,027 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Tyra Biosciences during the 4th quarter valued at approximately $31,000. Bank of New York Mellon Corp increased its stake in shares of Tyra Biosciences by 5.2% during the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company's stock worth $626,000 after purchasing an additional 2,221 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after purchasing an additional 3,236 shares during the period. Finally, US Bancorp DE purchased a new position in Tyra Biosciences in the fourth quarter valued at approximately $50,000. 84.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. Finally, Piper Sandler initiated coverage on Tyra Biosciences in a research report on Wednesday. They issued an "overweight" rating and a $33.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences currently has an average rating of "Buy" and an average target price of $30.83.

Tyra Biosciences Trading Down 1.7%

Shares of TYRA stock traded down $0.17 during trading hours on Thursday, reaching $9.59. The stock had a trading volume of 153,118 shares, compared to its average volume of 263,347. The stock's fifty day simple moving average is $9.46 and its 200 day simple moving average is $12.67. The firm has a market capitalization of $509.13 million, a PE ratio of -5.96 and a beta of 1.17. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.